Activation of G-protein-coupled receptors (GPCRs) leads to a cascade of signaling events, including calcium mobilization and downstream transcriptional activation of various proteins. Two commonly used methods of high-throughput screening for GPCRs include calcium-sensitive dyes, such as Fluo-4 NW, and reporter gene assays, such as beta-lactamase. To determine whether the advantages of each assay format could be combined by multiplexing, Jurkat and CHO-K1 cell lines overexpressing the M1 muscarinic receptor and beta-lactamase under control of an NFAT response element were tested in a multiplexed format. The Jurkat cell line was further screened with a subset of the LOPAC 1280 library. The multiplexing assay was compatible with both the CHO-K1 and Jurkat cell lines. For the screen, there was 100% correlation of on-target hits in the multiplexed format, and several false positives with each assay format were identified. Therefore, not only can the assays be multiplexed, but by multiplexing, the false positives associated with each assay format also could be easily identified. In addition to enhanced reliability, this method saves time and money because only half the amount of compounds, cells, and consumables are needed to screen a cell line in a multiplexed mode versus separate screening by both methods. (Journal of Biomolecular Screening 2006:644-651) 
INTRODUCTION
T HE G-PROTEIN-COUPLED RECEPTOR (GPCR) superfamily comprises an estimated 600 to 1000 members and is the largest known class of molecular targets with proven therapeutic value. Members of this family possess 7 transmembrane domains and are further grouped into families (A, B, C, and F/S) based on shared sequence motifs. 1 GPCRs are instrumental in the transmission of a diverse assortment of chemical messages from the extracellular environment to the interior of the cell and exhibit potent signaling due to the various secondmessenger cascades that are activated in response to a stimulus. GPCRs can be further classified based on the G proteins, which they couple to, and the signaling pathway activated by these G proteins. Gq-coupled receptors will lead to an increase in calcium mobilization and activation of downstream calciumdependent transcription factors such as NFAT. Gi/o-coupled receptors inhibit adenylate cyclase and lead to a reduction in cAMP levels. Gs-coupled receptors activate adenylate cyclase, which leads to increased levels of cAMP and activation of genes containing cAMP response elements. GPCRs have historically been, and continue to be, attractive drug targets due in part to their location on the cell surface, which makes them readily accessible to drugs. They are also ubiquitous, being involved in regulation of every major mammalian physiological system. GPCRs are involved in a wide range of disorders, including allergies, cardiovascular dysfunction, depression, obesity, cancer, pain, diabetes, and a variety of central nervous system disorders. In addition, the human genome contains several hundred unique GPCRs that have yet to be assigned a clear cellular function, giving GPCR targets a large therapeutic potential well into the future. More than 200 major prescription drugs target GPCRs, representing more than 30% of the total drugs on the market. 2, 3 Cellular assay screening is becoming increasingly popular in high-throughput screening (HTS) laboratories. Two of the most commonly used cellular screening methods for GPCRs are calcium flux assays and reporter gene assays. Each assay format has its advantages and disadvantages. The calcium flux assays are more proximal to the receptor but are most useful for Gq-coupled receptors or Gi/o-coupled receptors when combined with a promiscuous or chimeric G protein. Reporter genes can also measure Gq-coupled receptors and Gi/o-coupled receptors when combined with promiscuous or chimeric G proteins and also can directly measure Gs-coupled receptors through the natural signaling pathway. Another advantage is that reporter gene assays are very robust, producing assays with very high Z′ values (≥ 0.5), and these assays do not require specialized instrumentation with dispensing and reading capabilities, as is required for kinetic analysis of calcium signaling events.
One reporter gene assay that is increasingly used for GPCR screening is beta-lactamase. [4] [5] [6] [7] Beta-lactamase is a bacterial enzyme that has been developed as a reporter to detect gene expression in mammalian cells. Several reporter constructs, including a cAMP response element and a calcium-sensitive NFAT response element driving beta-lactamase expression, have been developed, each of which links beta-lactamase expression to receptor-mediated signal transduction events relevant to GPCR function. 8 Beta-lactamase activity can be detected with a Förster resonance energy transfer (FRET)-enabled substrate that generates a ratiometric reporter gene response with minimal experimental noise. 9 In the intact substrate molecule, excitation of a coumarin moiety at 409 nm results in transfer of energy to a fluorescein acceptor moiety, resulting in green light emission at ~520 nm from the cells. Cleavage of the substrate molecule by beta-lactamase results in separation of the coumarin and fluorescein moieties, a loss in FRET, and a resulting blue (~447 nm) emission from cells excited at 409 nm, and this ratio of 520-nm/447-nm emission is strictly determined by beta-lactamase activity. The ratiometric nature of substrate emission as a function of cleavage reduces the interference by technical variables, which can mask the underlying biological response of interest if undetected. Such measurement variables include fluctuation in cell number, transfection efficiency, substrate concentration, excitation path length, fluorescence detectors, and volume changes, and the ratiometric nature of the beta-lactamase readout corrects for such methodological issues to improve data quality.
The cost and effort involved in maintaining cells at peak performance for screening in cellular assays are high. 10 Simultaneous assay of distinct aspects of GPCR signaling might be expected to reduce the false positives resulting from any single assay while maintaining the cost and time efficiency of single-assay HTS. Methods that allow more information to be obtained from a single screen with fewer false positives would reduce both the time and cost of cellular assays. Therefore, to determine whether a calcium flux assay and a reporter gene assay could be successfully combined, we took advantage of the different kinetics of the 2 assay platforms to develop a multiplexed assay approach. In the multiplexed assay approach, cells are loaded with the calcium-sensitive dye, Fluo-4, and the assay readout is obtained. The cells are then returned to an incubator to allow time for the expression of the reporter gene. By the time the assay is ready to measure reporter activity, the signal from the Fluo-4 assay has faded, thereby allowing the readout of the beta-lactamase reporter without interference from the Fluo-4 signal. The multiplexed format was tested with the M1 muscarinic receptor expressed in a CHO-K1 or a Jurkat cell background stably expressing the beta-lactamase gene under control of an NFAT response element. The M1 NFAT-bla Jurkat cells were further tested in a multiplexed assay format to screen for M1 regulators in a subset of the LOPAC 1280 compound library.
MATERIALS AND METHODS

Materials
Jurkat and CHO-K1 cell lines stably expressing the M1 muscarinic receptor and beta-lactamase under control of an NFAT response element were obtained from Invitrogen Drug Discovery Solutions (Madison, WI). The Fluo-4 NW Calcium Assay Kit was obtained from Molecular Probes (Eugene, OR). The LiveBLAzer ™ FRET B/G Loading Kit was obtained from Invitrogen Drug Discovery Solutions (Madison, WI). Carbachol and the LOPAC 1280 library were obtained from Sigma-Aldrich (St. Louis, MO). All cell culture components were obtained from Invitrogen (Carlsbad, CA). The buffer used for the multiplexing experiment described is Hank's Balanced Salt Solution (HBSS) containing calcium (catalog #14025-092) supplemented with 25 mM HEPES buffer (pH 7.3), both obtained from Invitrogen (Carlsbad, CA). Assay plates used were black 384-well plates with clear bottoms (catalog #3712) from Costar (Cambridge, MA).
Cell culture
M1 NFAT-bla Jurkat cells were maintained between 1 × 10 5 and 2 × 10 6 cells/mL in RPMI 1640 supplemented with 10% dialyzed fetal bovine serum (FBS) and penicillin/streptomycin. M1 NFAT-bla CHO-K1 cells were maintained between 10% and 90% confluence in high-glucose Dulbecco's Modified Eagle Medium (DMEM) with Glutamax supplemented with 10% dialyzed FBS, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, 25 mM HEPES (pH 7.3), and penicillin/streptomycin.
Multiplexed assay for CHO-K1 cells
Fluo-4 NW was prepared according to the manufacturer's directions, except no probenecid was added to the Fluo-4 NW stock solution. For the M1 NFAT-bla CHO-K1 cells, cells were plated in a 384-well plate in phenol-red free DMEM containing 10% or 1% dialyzed FBS at a density of 10,000 cells/well in 18 µL. Cells were incubated overnight at 37 °C/5% CO 2 to allow the cells to adhere to the plate. The following day, an equal volume (18 µL) of Fluo-4 NW containing 2.5 mM probenecid was added to each well, or the media were removed from the wells and replaced with 36 µL of Fluo-4 NW diluted 2-fold in HBSS supplemented with 25 mM HEPES with or without 2.5 mM probenecid. Cells were incubated at 37 °C/5% CO 2 for 1 h. Plates were then placed at room temperature ~15 min until the time of the assay.
The CellLux with a 96-well head from PerkinElmer (Boston, MA) was used for compound addition and testing with Fluo-4 NW. A 10-sec baseline was obtained before cells were stimulated with 4 µL of 100 µM Carbachol or HBSS. Data are represented as the difference between the maximum stimulation value and the mean baseline fluorescence observed (∆F).
Following the Fluo-4 NW assay, the assay plates were returned to the 37 °C/5% CO 2 incubator for 5 h. A modified 6 × LiveBLAzer loading solution was prepared by combining 12 µL solution A, 30 µL solution B, and 958 µL solution C. Cells were loaded with 8 µL of the 6× loading solution for 2 h at room temperature. The CytoFluor plate reader from Applied Biosystems (Foster City, CA) was used for detection of the beta-lactamase signal using an excitation filter of 409/20 nm and emission filters of 460/40 nm and 530/30 nm. Data are represented as the blue/green ratio of each sample divided by the blue/green ratio of the unstimulated controls (response ratio).
Multiplexed assay plate preparation for Jurkat cells
Fluo-4 NW was prepared according to the manufacturer's directions, except no probenecid was added to the Fluo-4 NW stock solution. M1 NFAT-bla Jurkat cells were centrifuged at 200g for 5 min to remove the growth medium and were resuspended in HBSS supplemented with 25 mM HEPES buffer at a density of 3.3 × 10 6 cells/mL. The cell population was divided in 2 and the halves diluted 2-fold with either the Fluo-4 NW solution or HBSS supplemented with 25 mM HEPES buffer. Cells were then dispensed into the assay plates at a final cell density of 60,000 cells/well in 36 µL. For the LOPAC 1280 screen, four 384-well plates were prepared containing Fluo-4 NW, and four 384-well plates were prepared without Fluo-4 NW. The plates were incubated at 37 °C/5% CO 2 for 45 min. Plates were then placed at room temperature for ~30 min until the time of the assay.
LOPAC library stock plate preparation
A subset of twelve 96-well master stock plates from the LOPAC 1280 library were prepared at a final concentration of 100 µM in 1% DMSO. Columns 1 and 12 were left blank on each plate for controls.
Multiplexed screening with the M1-NFAT-bla Jurkat cell line
The M1 NFAT-bla Jurkat cell line was screened with the LOPAC 1280 library at a final concentration of 10 µM in 0.1% DMSO. Each 384-well cell plate contained a control column of wells without cells, 1 column of positive controls (10 µM Carbachol in 0.1% DMSO), and 2 columns of negative controls (0.1% DMSO). The CellLux was used for compound addition and the screening with Fluo-4 NW. Briefly, a 10-sec baseline read was obtained before addition of 4 µL of compounds to 1 quadrant of the 384-well assay plate. Data were then obtained for an additional 50 sec. Tips were changed in between each quadrant of each 384-well plate. Following compound addition, the plates were incubated at 37 °C/5% CO 2 for an additional 5 h. Cells were then loaded with the LiveBLAzer ™ FRET B/G kit as follows. For the multiplexed screen, a modified 6 × loading solution was prepared consisting of 6 µL solution A, 30 µL solution B, and 964 µL solution C. For the screen with beta-lactamase alone, a 6 × loading solution was prepared according to manufacturer's suggestions with 6 µL solution A, 60 µL solution B, and 934 µL solution C. Then, 8 µL of the respective 6 × loading solutions was added to each well of the multiplexed screening plates and the beta-lactamase screening plates. The plates were incubated at 22 °C for 1 h prior to reading the fluorescence values on a Cytofluor plate reader using the setting described above in the Multiplexed Assay for CHO-K1 Cells section.
Data analysis
Data for the Fluo-4 NW screen were analyzed using the AssayPro software contained with the CellLux by determining the maximum florescence value minus the mean baseline fluorescence value for each well. Microsoft Excel was used to compile all data from both screens.
RESULTS
Multiplexing assay development
To multiplex the Fluo-4 NW assay and the GeneBLAzer ® assay, conditions that were compatible with each assay format needed to be determined. For the M1 NFAT-bla CHO-K1 cells, several assay conditions were tested, including plating the cells overnight in phenol-red free DMEM containing 10% or 1% FBS and changing the media the next day to HBSS with or without probenecid or adding an equal volume of HBSS with probenecid to the DMEM. From this initial testing, it was determined that the CHO-K1 cells did not give an adequate Fluo-4 NW signal when the assay was run in HBSS without probenecid (Fig. 1) . Although the cells gave a good signal when run in HBSS containing probenecid, the subsequent GeneBLAzer ® assay was incompatible with these conditions (Fig. 1) . As HBSS was incompatible with the CHO-K1 cells for the GeneBLAzer ® assay, it was next investigated whether adding an equal volume of HBSS containing probenecid to cells in DMEM with 10% or 1% FBS would lead to acceptable signals. Both of these conditions gave acceptable Fluo-4 NW signals, but the beta-lactamase signal was reduced when the assay was performed in the assay media containing 1% FBS (Fig. 1) . Therefore, the recommended protocol for multiplexing CHO-K1 cells and other adherent cell types requiring probenecid is to plate the cells in complete media containing 10% FBS and then load the cells with an equal volume of the Fluo-4 NW in HBSS with probenecid and continue with the multiplexed protocol outlined in Figure 2 . By using these multiplexing media, the assay is homogeneous and does not require the media to be changed on the day of the assay. In addition, there was no significant shift in EC 50 observed in the Fluo-4 NW results by running the assay in the multiplexed media or in the HBSS with probenecid ( Fig. 3) . As the GeneBLAzer ® reporter gene assay is ratiometric in nature, any changes in confluency that may have occurred over the course of the assay are normalized in the final readout, but no significant changes in confluency were observed.
Conditions for the M1 NFAT-bla Jurkat cells were next tested. The manufacturer's recommended Fluo-4 NW buffer is HBSS supplemented with 25 mM HEPES and 2.5 mM probenecid.
However, Jurkat cells do not contain as high an activity of organic anion transporters as do the CHO-K1 cells; therefore, it was possible that the assay would perform well without the need for blocking these anion transporters as in the CHO-K1 cells. Consequently, we tested how the Jurkat cells would function when plated in HBSS with or without probenecid. Although the Fluo-4 NW assay functioned in HBSS assay buffer with or without probenecid, the signals from the betalactamase assay were greatly reduced when the assay was run 
FIG. 2.
A flowchart outlining the steps in the multiplexed Fluo-4 NW and GeneBLAzer ® assay. in HBSS containing probenecid (Fig. 4) . This negative effect of incubation of the cells with probenecid during the reporter gene assay was also noticed for the CHO-K1 cells (see Fig. 1 , HBSS + Probenecid condition). It is speculated that incubating the cells with probenecid for the 5 h required for the reporter gene assay in the absence of serum leads to some cellular toxicity, which prevents reporter gene activation and leads to the low GeneBLAzer ® signals. This effect of probenecid can be alleviated by running the assay in the absence of probenecid (as was done for the Jurkat cells) or for cells with active drug pumps that require probenecid (such as CHO-K1 cells) to add serum into the assay media. Probenecid does not have a negative effect on the reporter gene assay if added only during the betalactamase substrate-loading portion of the assay and not during the incubation with compounds (data not shown).
M1 NFAT-bla CHO-k1 Cells
Multiplexed Fluo-4 NW/GeneBLAzer ® screen versus GeneBLAzer ® screen
M1 NFAT-bla Jurkat cells were screened in a multiplexed Fluo-4 NW/GeneBLAzer ® assay using the procedure diagrammed in Figure 2 or with a standard protocol for GeneBLAzer ® . Carbachol was used as a positive control on each plate. For the beta-lactamase results, the blue/green ratio for each sample was divided by the blue/green ratio of the unstimulated negative control wells, and the resulting response ratio was plotted. For the Fluo-4 NW results, the mean baseline response was subtracted from the maximum stimulated response, and the resulting change in relative fluorescence units (∆F) was plotted. Screening results for the multiplexed assay format as well as GeneBLAzer ® alone are shown in Figure 5 . A threshold for each screening condition was set at 6 standard deviations from the average unstimulated control samples, and the hits from each screen were tabulated in Table 1 . As Fluo-4 NW is a single-wavelength emitter versus the ratiometric nature of beta-lactamase, there is more scatter in the data, which can be seen in the error bars of the positive controls plotted for each assay format (Fig. 5) . Representative images from the GeneBLAzer ® assay are shown in Figure 6 .
Ten compounds were positive in the multiplexed Fluo-4 NW and GeneBLAzer ® assays as well as in the GeneBLAzer ® screen alone. All 10 compounds were known acetylcholine receptor agonists. In addition to these 10 compounds, an additional 2 compounds were detected with the Fluo-4 NW assay. These compounds, daunorubicin and idarubicin, are both known to be fluorescent compounds and were thus false positives due to an interference effect. For the multiplexed GeneBLAzer ® assay, an additional 4 compounds were detected. Three of these compounds (thapsigargin, calcimycin, and cisplatin) are known to modulate intracellular calcium levels or to activate calmodulin and are off-target hits. Surprisingly, thapsigargin and calcimycin were not strong hits in the Fluo-4 NW assay despite the fact that both of these compounds modulate intracellular calcium levels. The fourth compound, NS 521 oxalate, is a benzimidazolone with neuroprotective properties whose mechanism of action is not well understood. These same 4 compounds were detected when the GeneBLAzer ® assay was used alone, but because of the small standard error associated with the negative controls in the GeneBLAzer ® data set, a very weak fifth hit, which was just above the 6 standard deviation threshold, was detected. This compound was L-741,626, a known D2 receptor antagonist. The data for the hits are summarized in the Venn diagram in Figure 7 .
The Venn diagram clearly shows the value of the multiplexing approach, as the true hits appear in the center of the diagram being identified by both assays in the multiplexed approach, and the false positives/off-target hits were unique to each assay method. These false-positives/off-target hits accounted for 37.5% of the total hits detected in the multiplexing assay.
DISCUSSION
The use of cellular assay in HTS is a growing trend that can offer several advantages. [11] [12] [13] These advantages include such things as the ability to distinguish between agonists, antagonists, and allosteric modulators and to provide information about acute cellular toxicity. However, growing and maintaining cells at the peak performance needed for screening is expensive and time-consuming. Therefore, it is advantageous to be able to obtain as much accurate information from a single screen as possible. By combining a Fluo-4 NW readout and a beta-lactamase reporter gene readout, this study demonstrates that hits can be verified with 2 independent assay readouts in the same well in a homogeneous assay format. This reduces the amount of compounds used because a single screen can provide information from both assay formats. In addition, the accuracy of the hits was increased by the combination of assays because we found a 100% correlation between the on-target hits with the 2 methods, whereas each method individually had several false positives/off-target hits. No false positives/false negatives were picked up by either assay. The false positives for the Fluo-4 NW assay included daunarubicin and idarubicin, 2 compounds known to be auto-fluorescent. The off-target hits for the betalactamase assay included thapsigargin, calcimycin, and cisplatin, 3 compounds known to modulate intracellular calcium levels or activate calmodulin. By using the multiplexing data and defining true hits as those that were active in both assay formats, 37.5% (6 of the 16 hits picked up in the multiplexing assay) of the compounds detected as potential positive hits (active in at least 1 assay format) were eliminated. These results show the advantage of multiplexing 2 different assay readouts for the same receptor. By multiplexing, only half the number of cells was needed as would have been needed for 2 separate screens, thus saving cell culture reagent cost as well as time. In addition, compounds and time were also saved during the screening as only a single-compound addition was needed versus the 2 compound additions needed with separate screens. There is some assay development that is required to determine an optimum assay buffer for the multiplexed screen, but even if the assays were to be run separately, assay buffers for each separate assay would still need to be optimized prior to screening. By multiplexing, the false positives could also easily be identified, which reduced the number of potential hits by 37.5%, which on a larger scale screening project would have been a significant number of compounds that would have needed to be picked for carrying forward into a secondary screen.
Alternatively, the 2 assays could be run sequentially, with 1 assay being used for the primary screen and the other assay used for the secondary screen. Although this would save on reagent costs for whichever assay is used as the secondary screen, the advantages of the time and cost savings in cell culture and screening would be lost, and a significantly larger number of false positives would be carried forward between the primary and secondary screens. But in cases in which the 2 assays could not be multiplexed, sequential assays would still remain an attractive option.
This multiplexing format should be broadly applicable as it has been shown to work with both suspension and adherent cell formats. However, different cellular backgrounds respond differently to assay buffers, as shown in the experiments using cell lines expressing the same receptor and reporter gene in 2 different cellular backgrounds (Jurkat and CHO-K1). The main variable to consider in assay buffer selection revolved around the use of probenecid. Incubation of the cellular assays for the time required for the reporter gene assay in assay media containing probenecid without serum led to detrimental effects on the reporter gene readout. If the cells do not have very active Compound # ∆RFU C organic anion transporters (like Jurkat cells), the multiplexed assay can be run in the absence of probenecid. However, if the cells do contain active organic anion transporters (like CHO-K1 cells), it was necessary to add serum into the assay media for proper reporter gene functioning. Therefore, the assay buffer used for multiplexing will need to be carefully considered, and parameters such as probenecid and serum concentration should be optimized for each cellular background of interest.
